Insilico Medicine’s AI-designed Parkinson’s drug cleared for human trials by FDA

The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies

Eyestem moves closer to blindness breakthrough with phase 2 trial green light

The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity

Lupin receives highest ESG rating from CDP for climate change and water security

Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability

Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator

This marks the second indication for which gumokimab has gained NDA review acceptance

Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy

The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026

Kindeva appoints David Stevens as new CEO

Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors

Symeres rehires Jurgen Berendsen as CFO amid strategic growth push

Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade

Codexis teams up with Axolabs to advance enzymatic RNA manufacturing

The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology

Avista Therapeutics unveils AI-powered expansion of gene therapy platform

The company is rolling out ARTEMIS, a next-generation AI platform for capsid design

US healthcare costs spark push for Ayurveda integration